Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Improved risk stratification in myeloma using a microRNA-based classifier.

Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, Kaiser M, Mirabella F, Wardell C, Gregory WM, Davies FE, Brewer D, Neri A, Morgan GJ.

Br J Haematol. 2013 Aug;162(3):348-59. doi: 10.1111/bjh.12394.

PMID:
23718138
2.

Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.

Anguiano A, Tuchman SA, Acharya C, Salter K, Gasparetto C, Zhan F, Dhodapkar M, Nevins J, Barlogie B, Shaughnessy JD Jr, Potti A.

J Clin Oncol. 2009 Sep 1;27(25):4197-203. doi: 10.1200/JCO.2008.19.1916. Erratum in: J Clin Oncol. 2012 Apr 20;30(12):1398.

3.

Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.

Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D, Luo JH.

Lancet Oncol. 2013 Dec;14(13):1295-306. doi: 10.1016/S1470-2045(13)70491-1. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.

PMID:
24239208
4.

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.

Kuiper R, van Duin M, van Vliet MH, Broijl A, van der Holt B, El Jarari L, van Beers EH, Mulligan G, Avet-Loiseau H, Gregory WM, Morgan G, Goldschmidt H, Lokhorst HM, Sonneveld P.

Blood. 2015 Oct 22;126(17):1996-2004. doi: 10.1182/blood-2015-05-644039.

5.

The role of circulating miRNAs in multiple myeloma.

Zhang J, Xiao X, Liu J.

Sci China Life Sci. 2015 Dec;58(12):1262-9. doi: 10.1007/s11427-015-4969-2. Review.

PMID:
26607481
6.

[Genetic tools for risk-stratification in multiple myeloma].

Braggio E, Albarracín Garramuño F.

Medicina (B Aires). 2013;73(4):369-75. Spanish.

7.

The potential of miRNAs as biomarkers for multiple myeloma.

Rocci A, Hofmeister CC, Pichiorri F.

Expert Rev Mol Diagn. 2014 Nov;14(8):947-59. doi: 10.1586/14737159.2014.946906. Review.

PMID:
25098410
8.

MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.

Li F, Xu Y, Deng S, Li Z, Zou D, Yi S, Sui W, Hao M, Qiu L.

Oncotarget. 2015 Nov 10;6(35):38270-82. doi: 10.18632/oncotarget.5681.

9.

The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.

Hose D, Seckinger A, Jauch A, Rème T, Moreaux J, Bertsch U, Neben K, Klein B, Goldschmidt H.

Srp Arh Celok Lek. 2011 Dec;139 Suppl 2:84-9.

10.

Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.

Meissner T, Seckinger A, Rème T, Hielscher T, Möhler T, Neben K, Goldschmidt H, Klein B, Hose D.

Clin Cancer Res. 2011 Dec 1;17(23):7240-7. doi: 10.1158/1078-0432.CCR-11-1628.

11.

Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis.

Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho WC, Yun JP, Zeng J, Liu LZ, Li L, Guo Y, Wang HY, Ma J.

Lancet Oncol. 2012 Jun;13(6):633-41. doi: 10.1016/S1470-2045(12)70102-X.

PMID:
22560814
12.

Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance.

Shi KQ, Lin Z, Chen XJ, Song M, Wang YQ, Cai YJ, Yang NB, Zheng MH, Dong JZ, Zhang L, Chen YP.

Oncotarget. 2015 Sep 22;6(28):25093-108. doi: 10.18632/oncotarget.4437.

13.

Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma.

Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, Li F, Qi F, Zhang Y, Yang Y, Zhan F, Qiu L.

Int J Cancer. 2015 Apr 15;136(8):1835-44. doi: 10.1002/ijc.29199.

14.

microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.

Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL, Huebner K.

Oncotarget. 2014 Mar 15;5(5):1174-84.

15.
16.

Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.

Bi C, Chung TH, Huang G, Zhou J, Yan J, Ahmann GJ, Fonseca R, Chng WJ.

Oncotarget. 2015 Sep 22;6(28):26508-18. doi: 10.18632/oncotarget.4769.

17.

Genomic profiling of myeloma: the best approach, a comparison of cytogenetics, FISH and array-CGH of 112 myeloma cases.

Rack K, Vidrequin S, Dargent JL.

J Clin Pathol. 2016 Jan;69(1):82-6. doi: 10.1136/jclinpath-2015-203054.

PMID:
26338801
18.

MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer.

Lu Y, Govindan R, Wang L, Liu PY, Goodgame B, Wen W, Sezhiyan A, Pfeifer J, Li YF, Hua X, Wang Y, Yang P, You M.

Carcinogenesis. 2012 May;33(5):1046-54. doi: 10.1093/carcin/bgs100.

19.

Functional Analysis of microRNA in Multiple Myeloma.

Di Martino MT, Amodio N, Tassone P, Tagliaferri P.

Methods Mol Biol. 2016;1375:181-94. doi: 10.1007/7651_2015_250.

PMID:
25971914
20.

Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients.

Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, Zamboni G, Maciejewski R.

Int J Cancer. 2013 Apr 1;132(7):1633-45. doi: 10.1002/ijc.27840.

Items per page

Supplemental Content

Support Center